Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Public authority · Norway
Industry association · Belgium
Declared costs: €10M+ a year · in the register since 2009
Medicinal products for human use · Monitoring and controlling drug precursors
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Norwegian Medicines Agency · filed 27 Apr 2021 · source
The proposed impact assessment will form a good foundation for revision of the general pharmaceutical legislation. We would however emphasise the importance of devoting sufficient attention to the proper functioning of the legislation regarding off-patent medicinal products. There are substantial differences in access, affordability, sustainability and security of supply for off patented and patented medicines.
Cefic · filed 27 Apr 2021 · source
EFCG, the European Fine Chemicals Group, represents European manufacturers of APIs, excipients and fine chemicals. As producers of the essential building blocks used to make medicines, we welcome the Commission’s initiative to ensure a future-proof and crisis-resistant medicines regulatory system that will allow all EU citizens full and equal access to safe, state-of-the-art therapies.
Norwegian Medicines Agency · filed 6 Jun 2023 · source
Designer precursors is a problem that the current legislation does not fully cover, so a targeted regulatory approach where the issue of designer precursors is included, is very favourable. Policy options 3 and 4 would create maximum impact. Norway has generic scheduling in the national narcotics regulation and considering a regulatory approach on EU-level where the same is done for precursors is very positive.
Cefic · filed 7 Jun 2023 · source
The European Chemical Industry fully supports EU legislation regulating the trade of drug precursors both intra EU and with non-EU countries. Our support is in line with our industrys Responsible Care® commitment to ensure safe, secure, responsible, and sustainable production and use of chemicals.
Cefic · filed 3 Apr 2026 · source
Cefic fully supports the Commissions work to strengthen the framework to prevent the misuse of drug precursors for illicit purposes, while reducing obstacles for legitimate trade. The EU chemical industry has a long-standing Responsible Care® commitment for safe, secure, responsible and sustainable production and use of chemicals, and shares the objective of ensuring that regulatory measures remain effective…
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.